The dry powder inhaler market is projected to be worth USD 20.83 billion in 2024. The market is likely to reach USD 29.95 ...

MNKD-201, an inhaled formulation of nintedanib for IPF, was shown to be safe and well tolerated in a clinical trial with ...

Though prescribing climate-friendly inhalers is environmentally sound, some experts warn certain patients may be overlooked.

In January, GlaxoSmithKline stopped producing Flovent, which was available as a prescription metered-dose inhaler (Flovent HFA) and a dry powder inhaler (Flovent Diskus). Both contain fluticasone ...

Innovata Biomed Ltd has developed an alternative device, the Clickhaler®, which is a multiple-dose dry powder inhaler (DPI). The present study compared patient acceptability of the salbutamol ...

Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced that it ...

Global pharma major Lupin Limited (Lupin) today announced its focus on formulating respiratory inhalers by incorporating a ...

Doctors may be taught to recommend dry powder inhalers as a more eco-friendly alternative, where suitable, as part of broader efforts to reduce healthcare's carbon footprint. The programme will ...

Cambridge Healthcare Innovations (CHI) has joined forces with Aptar Pharma in the US to commercialise the Science Park ...

Questionnaires were used by the investigators to assess the acceptability of the Clickhaler®, to compare it with that of the prestudy inhaler, and to assess patient technique. Four- or three ...